Similar articles

Abstract: Objective: To evaluate the efficacy and the indication of basic fibroblast growth factor (bFGF) in the treatment of exposure of orbital implants. Design: Retrospective and observational case series. Methods: We reviewed 41 patients (41 eyes) suffering exposure of orbital implants from Jan. 2000 to June 2006. The study group patients with mild exposure received combined treatment with bFGF and antibiotic drops, and while the control group patients with mild exposure were treated with antibiotic drops only. The study group patients with moderate and severe exposure received combined treatment with bFGF and antibiotic drops, and after 2 months they were subjected to amniotic membrane transplantation, while the control group patients with moderate and severe exposure underwent amniotic membrane transplantation after using antibiotic drops. Observation of the growth of conjunctival epithelium and comparison of the healing rate of the two groups. Results: The healing rates of the mild, moderate and severe exposure study group were 100% and 92.3%. The healing rates of the mild, moderate and severe exposure control group were 55.6% and 66.7% respectively. The difference of the healing rates of the mild exposure study group and the control group was significant (P=0.033). And the difference of the healing rates of the moderate and severe exposure study group and the control group was not significant (P=0.167). Conclusion: bFGF may promote obviously the healing of orbital implant exposure, particularly it can be the first choice for the treatment of mild degree exposure. For the moderate and severe cases, it can be administered before surgical repair to enhance neovascularization and will tend to increase the success rate of surgical repair.

[1] Buettner, H., Bartley, G.B., 1992. Tissue breakdown and exposure associated with orbital hydroxyapatite implants. Am. J. Ophthalmol., 113(6):669-673.

[2] Cui, H.G., Chen, Y.H., Li, H.Y., 2005. Clinical effect of amniotic membrane transplantation for reconstruction of conjunctival sac combined with orbital implantation. Zhonghua Yan Ke Za Zhi, 41(11):1005-1008 (in Chinese).

[3] Custer, P.L., Trinkaus, K.M., 2007. Porous implant exposure: incidence, management, and morbidity. Ophthalmic Plast. Reconstr. Surg., 23(1):1-7.

[4] Goldberg, R.A., Holds, J.B., 1992. Exposed hydroxyapatite orbital implants: report of six cases. Ophthalmology, 99(5):831-836.

[5] Lee-Wing, M.W., 2003. Amniotic membrane for repair of exposed hydroxyapatite orbital implant. Ophthalmic Plast. Reconstr. Surg., 19(5):401-402.

[6] Li, Y.P., Lin, J.X., Tang, Z.H., Liang, D., Fang, H.Z., Zhou, S.S., Feng, G.G., Yi, Y.Z., 1998. The experimental studies of the epithelial healing of cornea in the alkali-injure rabbit eye promoted by recombinant basic fibroblast growth factor. Yan Wai Shang Zhi Ye Yan Bing Za Zhi, 20(5):403-404 (in Chinese).

[7] Nicaeus, T.E., Tolention, M.J., Adamis, A.P., Rubin, P.A., 1996. Sucralfate and basic fibroblast growth factor promote endothelial cell proliferation around porous alloplastic implants in vitro. Ophthalmic Plast. Reconstr. Surg., 12(2):235-239.

[8] Nunery, W.R., Heinz, G.W., Bonnin, J.M., Martin, R.T., Cepela, M.A., 1993. Exposure rate of hydroxyapatite spheres in the anophthalmic socket: histopathologic correlation and comparison with silicone sphere implants. Ophthalmic Plast. Reconstr. Surg., 9(2):96-104.

[9] Oestreicher, J.H., Liu, E., Berkowitz, M., 1997. Complications of hydroxyapatite orbital implants. Ophthalmology, 104(2):324-329.

[10] Park, W.C., Han, S.K., Kim, N.J., Chung, T.Y., Khwarq, S.I., 2005. Effect of basic fibroblast growth factor on fibrovascular ingrowth into porous polyethylene anophthalmic socket implants. Korean J. Ophthalmol., 19(1):1-8.

[11] Remulla, H.D., Rubin, P.A., Shore, J.W., Sutula, F.C., Townsend, D.J., Woog, J.J., Jahrling, K.V., 1995. Complications of porous spherical orbital implants. Ophthalmology, 102(4):586-593.

[12] Rubin, P.A., Nicaeus, T.E., Warner, M.A., Remulla, H.D., 1997. Effect of sucralfate and basic fibroblast growth factor on fibrovascular ingrowth into hydroxyapatite and porous polyethylene alloplastic implants using a novel rabbit model. Ophthalmic Plast. Reconstr. Surg., 13(1):8-17.

[13] Sagoo, M.S., Olver, J.M., 2004. Autogenous temporalis fascia patch graft for porous polyethylene (Medpor) sphere orbital implant exposure. Br. J. Ophthalmol., 88(7):942-946.

[14] Shields, C.L., Shields, J.A., de Potter, P., Singh, A.D., 1994. Problems with the hydroxyapatite orbital implant: experience with 250 consecutive cases. Br. J. Ophthalmol., 78(9):702-706.

[15] Soparkar, C.N., Wong, J.F., Patrinely, J.R., Appling, D., 2000. Epidermal and fibroblast growth factors enhance fibrovascular integration of porous polyethylene implants. Ophthalmic Plast. Reconstr. Surg., 16(5):337-340.

[16] Tawfik, H.A., Budin, H., Dutton, J.J., 2005. Repair of exposed porous polyethylene implants utilizing flaps from the implant capsule. Ophthalmology, 112(3):516-523.

[17] Woo, K.I., Kim, J.M., Chang, H.R., Kim, M.S., Kim, Y.D., Lee, J.H., 2000. The effect of growth factors and surgical procedures on fibrovascular ingrowth into anophthalmic socket implant of porous polyethylene. J. Korean Ophthalmol. Soc., 41(12):2725-2731.

[18] Yang, Z.Q., Wang, G.X., 2005. Amniotic membrane transplantation treatment of 29 patients with implanted ocular prosthesis exposure. Journal of Xinxiang Medical College, 22(4):381-382 (in Chinese).

[19] Yang, X.H., Ding, Z.P., Mai, C.K., He, Y.L., Wei, H.R., Lv Y.S., 1997. Basic fibroblast growth factor induced corneal neovascularization in vivo. Chin. J. Pract. Ophthalmol., 15(10):734-737 (in Chinese).